Celtaxsys

Celtaxsys is a clinical-stage drug development company dedicated to advancing novel foundational therapies to treat inflammation in rare orphan-designated diseases. The company's flagship investigational drug, acebilustat, aims to preserve lung function in cystic fibrosis (CF) by specifically modulating key aspects of dysregulated (i.e., overactive) immune responses. The company is committed to researching whether treatment with acebilustat, in combination with existing therapies, can help restore balance, or a more "normalized" immune response in patients, thereby improving their quality of life.